SE Pincus

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
HIV resistance to approved therapeutics is an increasing concern necessitating the need for development of new therapeutic approaches. Elusys's novel Heteropolymer (HP) technology consists of two monoclonal antibodies that are chemically cross-linked: one specific for complement receptor type 1 (CR1, CD35) on red blood cells (RBCs) and the other recognizing(More)
  • 1